Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

Vaccine

Volumn 22, Issue 1, 2003, Pages 30-41

  Genton, Blaise ^a,b   Al Yaman, Fadwa ^a   Betuela, Inoni ^a   Anders, Robin F ^c,d   Saul, Allan ^e   Baea, Kay ^a   Mellombo, Mata ^a   Taraika, Jack ^a   Brown, Graham V ^c   Pye, David ^f   Irving, David O ^g   Felger, Ingrid ^b   Beck, Hans Peter ^b   Smith, Thomas A ^b   Alpers, Michael P ^a  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d The Cooperative Research Centre for Vaccine Technology   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f CSL LIMITED   (Australia)

^g Biotechnology Australia   (Australia)

Author keywords

Immunogenicity; Malaria vaccine; MSP1; MSP2; Papua New Guinea; Phase I; Plasmodium falciparum; RESA; Safety

Indexed keywords

FANSIDAR; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MONTANIDE ISA 720; RING INFECTED ERYTHROCYE SURFACE ANTIGEN; RO 45 2067; RO 45 2164; RO 46 2924; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; COMMON COLD; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE RESPONSIVE ELEMENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; EDEMA; EMULSION; FEMALE; GAIT DISORDER; HEADACHE; HEARING DISORDER; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MORBIDITY; NAUSEA; OTALGIA; PAIN; PAPUA NEW GUINEA; PARASITE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THIGH; VOMITING;

EID: 10744225159     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00536-X     Document Type: Article

References (20)

1. Bojang K.A., Milligan P.J.M., Pinder M., Vigneron L., Alloueche A., Kester K.E.et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 358:2001;1927-1934.
2. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A.et al. A blood-stage malaria vaccine (MSP1, MSP2, RESA) reduces Plasmodium falciparum density and exerts a selective pressure on parasite populations in a phase I/ IIb trial in Papua New Guinea. J. Infect. Dis. 185:2002;820-827.
3. Lawrence G., Cheng Q.Q., Reed C., Taylor D., Stowers A., Cloonan N.et al. Effect of vaccination with three recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 18:2000;1925-1931.
4. Alpers M.P., Al-Yaman F., Beck H.-P., Bhatia K.K., Hii J., Lewis D.J.et al. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies. PNG Med. J. 35:1992;285-297.
5. Al-Yaman F., Genton B., Kramer K., Chang S.P., Hui G.S., Baisor M.et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am. J. Trop. Med. Hyg. 54:1996;443-448.
6. Al-Yaman F., Genton B., Anders R., Taraika J., Ginny M., Mellor S.et al. Assessment of the role of humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol. 17:1995;493-501.
7. Al-Yaman F., Genton B., Taraika J., Anders R., Alpers M.P. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. Parasite Immunol. 19:1997;249-254.
8. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC Montanide ISA 720. Vaccine. 15:1997;176-178.
9. Saul A., Lawrence G., Smillie A., Rzepczyk C.M., Reed C., Taylor D.et al. Human phase I vaccine trials of three recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine. 17:1999;3145-3159.
10. Genton B., Al-Yaman F., Anders R., Saul A., Brown G., Pye D.et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine. 18:2000;2504-2511.
11. Toledo H., Baly A., Castro O., Resik S., Laferte J., Rolo F.et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine. 19:2001;4328-4336.
12. Holder A.A. The precursor to major merozoite surface antigens: structure and role in immunity. Prog. Allergy. 41:1988;72-97.
13. Smythe J.A., Coppel R.L., Day K.P., Martin R.K., Oduola A.M., Kemp D.J. et al. Structural diversity in the Plasmodium falciparum merozoite surface antigen 2. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1751-1755.
14. Stuerchler D., Berger R., Rudin C., Just M., Saul A., Rzepczyk C.et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am. J. Trop. Med. Hyg. 53:1995;423-431.
15. Culvenor J.G., Day K.P., Anders R.F. Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion. Infect. Immun. 59:1991;1183-1187.
16. Hii J.L., Smith T., Mai A., Mellor S., Lewis D., Alexander N.et al. Spatial and temporal variation in abundance of Anopheles (Diptera:Culicidae) in a malaria endemic area in Papua New Guinea. J. Med. Entomol. 34:1997;193-205.
17. Genton B., Al-Yaman F., Beck H.-P., Hii J., Narara A., Gibson N.et al. The epidemiology of malaria in the Wosera area, East Sepik Province of Papua New Guinea. Ann. Trop. Med. Parasitol. 89:1995;359-376.
18. Genton B., Al-Yaman F., Beck H.-P., Hii J., Mellor S., Rare L.et al. The epidemiology of malaria in the Wosera area, East Sepik Province of Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann. Trop. Med. Parasitol. 89:1995;377-390.
19. Müller I., Smith T., Mellor S., Rarea L., Genton B. The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Int. J. Epidemiol. 27:1998;878-884.
20. Genton B., Smith T., Baea K., Narara A., Al-Yaman F., Beck H.P.et al. Malaria: how useful are clinical criteria for improving the diagnosis among presumptive cases in a highly endemic area? Trans. R. Soc. Trop. Med. Hyg. 88:1994;537-541.